Xianxi Tan

Xianxi Tan

Auto-generated profile, based on publicly available information

Xianxi Tan

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
RGRuili Guo
Ruili Guo
XWXue Wang
Xue Wang
YFYani Fang
Yani Fang
XCXiongjian Chen
Xiongjian Chen
KCKun Chen
Kun Chen
LLLi Lin
Li Lin
The pathology of cerebrovascular disorders takes an important role in traumatic brain injury (TBI) by increasing intracranial pressure. Fibroblast growth factor 20 (FGF20) is a brain-derived neurotrophic factor, that has been shown to play an important role in the survival of dopaminergic neurons and the treatment of Parkinson's disease (PD). However, little is known about the role of FGF20 in the treatment of TBI and its underlying mechanism. The purpose of this study was to evaluate the protective effect of recombinant human FGF20 (rhFGF20) on protecting cerebral blood vessels after TBI. In this study, we indicated that rhFGF20 could reduce brain edema, Evans blue penetration and upregulated the expression of blood-brain barrier (BBB)-related tight junction (TJ) proteins, exerting a protective effect on the BBB in vivo after TBI. In the TBI repair phase, rhFGF20 promoted angiogenesis, neurological and cognitive function recovery. In tumor necrosis factor-α (TNF-α)-induced human brain microvascular endothelial cells (hCMEC/D3), an in vitro BBB disruption model, rhFGF20 reversed the impairment in cell migration and tube formation induced by TNF-α. Moreover, in both the TBI mouse model and the in vitro model, rhFGF20 increased the expression of β-catenin and GSK3β, which are the two key regulators in the Wnt/β-catenin signaling pathway. In addition, the Wnt/β-catenin inhibitor IWR-1-endo significantly reversed the effects of rhFGF20. These results indicate that rhFGF20 may prevent vascular repair and angiogenesis through the Wnt/β-catenin pathway.

17 April 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
BZBing Zhao
Bing Zhao
XTXianxi Tan
Xianxi Tan
HYHua Yang
Hua Yang
KZKuang Zheng
Kuang Zheng
ZLZequn Li
Zequn Li
AIAMPAS investigators
AMPAS investigators
Poor-grade aneurysmal subarachnoid hemorrhage (aSAH) is associated with very high mortality and morbidity. Our limited knowledge on predictors of long-term outcome in poor-grade patients with aSAH definitively managed comes from retrospective and prospective studies of small case series of patients in single center. The purpose of the AMPAS is to determine the long-term outcomes in poor-grade patients with different managements within different time after aSAH, and identify the independent predictors of the outcome that help guide the decision on definitive management. The AMPAS study is a prospective, multicenter, observational registry of consecutive hospitalized patients with poor grade aSAH (WFNS grade IV and V). The aim is to enroll at least 226 poor-grade patients in 11 high-volume medical centers (eg, >150 aSAH cases per year) affiliated to different universities in China. This study will describe poor grade patients and aneurysm characteristics, treatment strategies (modality and time of definitive management), hospitalization complications and outcomes evolve over time. The definitive management is ruptured aneurysm treatment. Outcomes at 3, 6, 12 months after the management were measured using the Glasgow Outcome Scale and the Modified Rankin Scale. The AMPAS is the first prospective, multicenter, observational registry of poor grade aSAH with any management. This study will contribute to a better understanding of significant predictors of outcome in poor grade patients and help guide future treatment of the worst patients after aSAH. Chinese Clinical Trial Registry: ChiCTR-TNRC-10001041 .

23 March 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
WHWen-Ting Huang
Wen-Ting Huang
XCXiong-Jian Chen
Xiong-Jian Chen
YLYu-Kai Lin
Yu-Kai Lin
JSJun-Feng Shi
Jun-Feng Shi
HLHong Li
Hong Li
PWPeng Wang
Peng Wang

7 May 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYeli Zhao
Yeli Zhao
SYShasha Ye
Shasha Ye
JLJingjing Lin
Jingjing Lin
FLFei Liang
Fei Liang
JCJun Chen
Jun Chen
XTXianxi Tan
Xianxi Tan
Diabetes increases the risk of stroke, exacerbates neurological deficits, and increases mortality. Non-mitogenic fibroblast growth factor 1 (nmFGF1) is a powerful neuroprotective factor that is also regarded as a metabolic regulator. The present study aimed to investigate the effect of nmFGF1 on the improvement of functional recovery in a mouse model of type 2 diabetic (T2D) stroke. We established a mouse model of T2D stroke by photothrombosis in mice that were fed a high-fat diet and injected with streptozotocin (STZ). We found that nmFGF1 reduced the size of the infarct and attenuated neurobehavioral deficits in our mouse model of T2D stroke. Angiogenesis plays an important role in neuronal survival and functional recovery post-stroke. NmFGF1 promoted angiogenesis in the mouse model of T2D stroke. Furthermore, nmFGF1 reversed the reduction of tube formation and migration in human brain microvascular endothelial cells (HBMECs) cultured in high glucose conditions and treated with oxygen glucose deprivation/re-oxygenation (OGD). Amp-activated protein kinase (AMPK) plays a critical role in the regulation of angiogenesis. Interestingly, we found that nmFGF1 increased the protein expression of phosphorylated AMPK (p-AMPK) both in vivo and in vitro. We found that nmFGF1 promoted tube formation and migration and that this effect was further enhanced by an AMPK agonist (A-769662). In contrast, these processes were inhibited by the application of an AMPK inhibitor (compound C) or siRNA targeting AMPK. Furthermore, nmFGF1 ameliorated neuronal loss in diabetic stroke mice via AMPK-mediated angiogenesis. In addition, nmFGF1 ameliorated glucose and lipid metabolic disorders in our mouse model of T2D stroke without causing significant changes in body weight. These results revealed that nmFGF1-regulated glucolipid metabolism and angiogenesis play a key role in the improvement of functional recovery in a mouse model of T2D stroke and that these effects are mediated by the AMPK signaling pathway.

17 May 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YZYeli Zhao
Yeli Zhao
SYShasha Ye
Shasha Ye
JLJingjing Lin
Jingjing Lin
FLFei Liang
Fei Liang
JCJun Chen
Jun Chen
XTXianxi Tan
Xianxi Tan
[This corrects the article DOI: 10.3389/fphar.2021.680351.].